Table 3.
Effects of constitutive overexpression of PLM S68E on levels of selected proteins
| Wild-type | ConS68E | |
|---|---|---|
| 4 wk | ||
| NCX1 | 260.5 ± 9.2 (5) | 244.1 ± 9.5 (4) |
| SERCA2 | 151.1 ± 5.5 | 101.3 ± 6.2* |
| α1, Na+-K+-ATPase | 109.5 ± 11.9 | 101.4 ± 9.8 |
| α2, Na+-K+-ATPase | 161.6 ± 5.9 | 161.4 ± 7.2 |
| Cav1.2 | 111.1 ± 12.6 | 135.3 ± 2.5* |
| RyR2 | 184.0 ± 14.3 | 192.5 ± 48.8 |
| p-RyR2 | 160.2 ± 21.4 | 123.0 ± 17.3 |
| Calsequestrin | 380.2 ± 13.2 | 330.3 ± 31.0 |
| 22 wk | ||
| NCX1 | 223.4 ± 2.3 (5) | 225.9 ± 6.9 (4) |
| SERCA2 | 526.2 ± 27.0 | 529.6 ± 43.1 |
| α1, Na+-K+-ATPase | 218.0 ± 9.4 | 196.2 ± 5.8 |
| α2, Na+-K+-ATPase | 91.8 ± 17.3 | 105.4 ± 22.3 |
| Calsequestrin | 465.9 ± 21.1 | 416.0 ± 39.6 |
Values (in arbitrary units) are means ± SE. Numbers in parentheses are numbers of hearts. NCX1, cardiac Na+/Ca2+ exchanger; PLM, phospholemman; SERCA2, sarco(endo)plasmic reticulum Ca2+-ATPase; Cav1.2, α-subunit of L-type Ca2+ channel; RyR2, cardiac ryanodine receptor; p-RyR2, ryanodine receptor phosphorylated at serine2808.
*
P < 0.02, wild-type versus conS68E.